K36 Therapeutics Announces $70 Million Series B Financing To Fund Clinical Proof Of Concept Of Ktx-1001, First-In-Class Inhibitor Of Mmset For Treatment Of Multiple Myeloma Patients With Genetic Translocation (4;14)
Amount Raised
$70 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareInvestors
Description
K36 Therapeutics ("K36"), a privately held clinical-stage biotech company developing KTX-1001, an investigational small molecule methyltransferase inhibitor of multiple myeloma SET (MMSET) domain, today announced a $70M Series B financing. The round was led by Nextech Invest, Ltd, a precision medicine focused investment firm, on behalf of one or more funds managed by it, with participation from Bristol Myers Squibb Company (NYSE:BMY), and other undisclosed investors. All existing investors including Atlas Venture, F-Prime Capital, and Eight Roads Ventures participated in the round.
Quick answer
K36 Therapeutics raised $70 Million in a Series B round, dated June 28, 2023. Investors: Eight Roads Ventures, F Prime Capital, Atlas Venture, Bristol Myers Squibb Company and Nextech Invest, Ltd. K36 Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did K36 Therapeutics raise?
- K36 Therapeutics raised $70 Million in a Series B round on June 28, 2023.
- Who invested in K36 Therapeutics?
- Eight Roads Ventures, F Prime Capital, Atlas Venture, Bristol Myers Squibb Company and Nextech Invest, Ltd are named as investors in this round.
- What does K36 Therapeutics do?
- Founded in February 2021, K36 is a privately held biotech company backed by Atlas Venture, F-Prime Capital, Eight Roads Capital, Nextech and Bristol Myers Squibb.
- Where is K36 Therapeutics based and how big is it?
- K36 Therapeutics is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at K36 Therapeutics?
- Fundz holds 1 contact at K36 Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as K36 Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Abcuro raised $120M on August 11, 2023.
- MindMed raised $7M on August 11, 2023.
- Zetagen Therapeutics raised an undisclosed amount (Series B) on August 11, 2023.
- HAGAR raised an undisclosed amount (Funding Round) on August 10, 2023.
- ADARx Pharmaceuticals, Inc. raised $200M (Series C) on August 9, 2023.
- Fore Biotherapeutics raised $62M on August 9, 2023.
Who to call at K36 Therapeutics, and when
A new round usually means K36 Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day K36 Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at K36 Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at K36 Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment K36 Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansK36 Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.